Excision Repair Cross-Complementing Group-1 (ERCC1) Induction Kinetics and Polymorphism Are Markers of Inferior Outcome in Patients With Colorectal Cancer Treated With Oxaliplatin

Oncotarget - United States
doi 10.18632/oncotarget.27140
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

ERCC1 (Excision Repair Complementing Defective Repair in Chinese Hamster)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Association Between Excision Repair Cross-Complementation Group 1 Polymorphism and Clinical Outcome of Platinum-Based Chemotherapy in Patients With Epithelial Ovarian Cancer

Experimental & Molecular Medicine
2006English

Association Studies of Excision Repair Cross-Complementation Group 1 (ERCC1) Haplotypes With Lung and Head and Neck Cancer Risk in a Caucasian Population

Cancer Epidemiology
Cancer ResearchEpidemiologyOncology
2011English

Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

The Prognostic and Predictive Value of Excision Repair Cross-Complementation Group 1 (ERCC1) Protein in 1288 Patients With Head and Neck Squamous Cell Carcinoma Treated With Platinum-Based Therapy: A Meta-Analysis

European Archives of Oto-Rhino-Laryngology
MedicineOtorhinolaryngology
2015English

Correlation of ERCC1 Expression in Peripheral Blood Lymphocytes With Outcomes of Patients With Gastric Cancer Treated With Oxaliplatin-Based Adjuvant Chemotherapy

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Let-7 miRNA-binding Site Polymorphism in the KRAS 3′UTR; Colorectal Cancer Screening Population Prevalence and Influence on Clinical Outcome in Patients With Metastatic Colorectal Cancer Treated With 5-Fluorouracil and Oxaliplatin +/− Cetuximab

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

miR‑138‑5p Modulates the Expression of Excision Repair Cross‑complementing Proteins ERCC1 and ERCC4, and Regulates the Sensitivity of Gastric Cancer Cells to Cisplatin

Oncology Reports
MedicineCancer ResearchOncology
2018English

AB153. Down-Regulated Expression of Excision of Repair Cross-Complementing Gene 1 Reduces Resistance to Hydroxycamptothecine in Bladder Cancer

Translational Andrology and Urology
Reproductive MedicineUrology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy